Blood-based biomarkers have taken off in the Alzheimer’s disease research space in recent years and extensive efforts are underway to validate these measures for use in clinical practice. Alicia Algeciras-Schimnich, PhD, Mayo Clinic, Rochester, MN, describes the importance of longitudinal data when evaluating the performance of a biomarker assay, to see how robust and reproducible it is over time. This is important in diagnosis, as it ensures the positive and negative outcomes of the assay do not change over time, as well as allowing more rigorous comparison to other assays investigating the same biomarker. Currently, blood-based biomarkers are widely used in research and some are being implemented in clinical trials for recruitment and to support efficacy assessments, but the ultimate aim is to evaluate their use in clinical practice. This needs to be investigated, as Dr Algeciras-Schimnich’s research and that of others show that not all assays perform equally. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
